Document is current
Any future updates will be listed below
-
Authors
Kwak, Suryang http://orcid.org/0000-0002-5202-8326
Choi, JooHee
Hink, Tiffany
Reske, Kimberly A.
Blount, Kenneth
Jones, Courtney
Bost, Margaret H.
Sun, Xiaoqing
Burnham, Carey-Ann D.
Dubberke, Erik R.
Dantas, Gautam
,
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention (5U54CK000162)
- License Information
-
More Information
Article History
Received: 30 June 2020
Accepted: 11 August 2020
First Online: 31 August 2020
Ethics approval and consent to participate
: Participants of the Rebiotix Phase 2b study were enrolled at 21 centers in the USA and Canada from 10 December 2014 through 13 November 2015. The study protocol received institutional review board approval at each center. All participants provided written informed consent [].
: Not applicable
: Rebiotix provided access to study specimens and data, and reviewed the manuscript prior to submission, but was not involved in this study’s design, specimen processing, data analysis, or interpretation. Erik R. Dubberke is a consultant for Sanofi, Pfizer, Synthetic Biologics, BioK+, and Rebiotix, and has a grant from Pfizer.
